Flash Endo Insulin-like meds

Patients with diabetes mellitus type 1 and type 2 who use mealtime insulin and have not achieved desired glucose control.

Yes, nausea is a common side effect of pramlintide, especially when starting the medication or increasing the dose.

Pramlintide and insulin should be administered as separate injections, and the insulin dose may need to be adjusted to reduce the risk of insulin-induced hypoglycemia.

The safety of pramlintide during pregnancy has not been established. Its use should be discussed with a healthcare provider, weighing the potential benefits against potential risks.

The nurse should educate the patient on the signs and symptoms of hypoglycemia, emphasizing the increased risk within 3 hours following a pramlintide injection. The patient should be advised to monitor blood glucose levels closely, especially if a meal is skipped or delayed.

GLP-1 receptor agonists are indicated primarily for the treatment of type 2 diabetes mellitus.

Common gastrointestinal side effects include nausea, vomiting, diarrhea, and decreased appetite.

Patients should be monitored for signs and symptoms of pancreatitis. If pancreatitis is suspected, the GLP-1 receptor agonist should be discontinued promptly.

The safety of GLP-1 receptor agonists during pregnancy is not well established. They should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The nurse should inform the patient that liraglutide is usually administered once daily, regardless of meals, but it's essential to take it at the same time each day to maintain consistent blood levels.